Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis
Objectives: To compare the liver safety profile of interferon ? (IFN ?) and teriflunomide in patients with multiple sclerosis. Methods: A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN ? with teriflunomide, or disease-mod...
Autores Principales: | , , , , , |
---|---|
Formato: | Artículo (Article) |
Lenguaje: | Inglés (English) |
Publicado: |
Elsevier B.V.
2018
|
Materias: | |
Acceso en línea: | https://repository.urosario.edu.co/handle/10336/22632 https://doi.org/10.1016/j.msard.2018.09.014 |
id |
ir-10336-22632 |
---|---|
recordtype |
dspace |
spelling |
ir-10336-226322022-05-02T12:37:17Z Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis Salas P.A.O. Parra C.O. Florez C.E.P. Goez L.M. Velez-van-Meerbeke, Alberto Rodriguez J.H. Alemtuzumab Beta interferon Daclizumab Fingolimod Glatiramer Placebo Teriflunomide Beta interferon Crotonic acid derivative Immunologic factor Teriflunomide Toluidine derivative Article Drug efficacy Drug safety Human Hypertransaminasemia Liver function Liver function test Meta analysis Multiple sclerosis Systematic review Toxic hepatitis Treatment outcome Comparative study Drug effect Liver Multiple sclerosis Toxic hepatitis Chemical and drug induced liver injury Crotonates Humans Immunologic factors Interferon-beta Liver Multiple sclerosis Toluidines Interferon ? Liver safety profile Multiple sclerosis Teriflunomide Objectives: To compare the liver safety profile of interferon ? (IFN ?) and teriflunomide in patients with multiple sclerosis. Methods: A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN ? with teriflunomide, or disease-modifying drugs, or placebo in RRMS were included. An indirect comparison network meta-analysis within a Bayesian framework with STATA (version 13.0) was done for this study. Results: The database searches yielded 284 titles, with 15 records as duplicates. One study was identified by manually searching. Thirteen articles were included in the systematic review. Twelve studies compared IFN ? (4203 patients) vs another DMT. Four studies evaluated the effectiveness and safety of teriflunomide (906 patients) vs another DMT. Six studies reported drug-induced liver injury as per the Hy's Law. However, only one study had a direct comparison and reported no cases of liver toxicity in either group, so it was not possible to estimate the OR. The indirect comparisons metanalysis shows that there was no statistically-significant difference between teriflunomide and IFN ? (OR 1.09, 95% CI 0.02–2.16). Conclusions: There were no significant difference when comparing IFN ? and teriflunomide in terms of liver failure or elevation of transaminases. © 2018 2018 2020-05-25T23:57:13Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 22110348 https://repository.urosario.edu.co/handle/10336/22632 https://doi.org/10.1016/j.msard.2018.09.014 eng info:eu-repo/semantics/openAccess application/pdf Elsevier B.V. instname:Universidad del Rosario |
institution |
EdocUR - Universidad del Rosario |
collection |
DSpace |
language |
Inglés (English) |
topic |
Alemtuzumab Beta interferon Daclizumab Fingolimod Glatiramer Placebo Teriflunomide Beta interferon Crotonic acid derivative Immunologic factor Teriflunomide Toluidine derivative Article Drug efficacy Drug safety Human Hypertransaminasemia Liver function Liver function test Meta analysis Multiple sclerosis Systematic review Toxic hepatitis Treatment outcome Comparative study Drug effect Liver Multiple sclerosis Toxic hepatitis Chemical and drug induced liver injury Crotonates Humans Immunologic factors Interferon-beta Liver Multiple sclerosis Toluidines Interferon ? Liver safety profile Multiple sclerosis Teriflunomide |
spellingShingle |
Alemtuzumab Beta interferon Daclizumab Fingolimod Glatiramer Placebo Teriflunomide Beta interferon Crotonic acid derivative Immunologic factor Teriflunomide Toluidine derivative Article Drug efficacy Drug safety Human Hypertransaminasemia Liver function Liver function test Meta analysis Multiple sclerosis Systematic review Toxic hepatitis Treatment outcome Comparative study Drug effect Liver Multiple sclerosis Toxic hepatitis Chemical and drug induced liver injury Crotonates Humans Immunologic factors Interferon-beta Liver Multiple sclerosis Toluidines Interferon ? Liver safety profile Multiple sclerosis Teriflunomide Salas P.A.O. Parra C.O. Florez C.E.P. Goez L.M. Velez-van-Meerbeke, Alberto Rodriguez J.H. Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
description |
Objectives: To compare the liver safety profile of interferon ? (IFN ?) and teriflunomide in patients with multiple sclerosis. Methods: A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN ? with teriflunomide, or disease-modifying drugs, or placebo in RRMS were included. An indirect comparison network meta-analysis within a Bayesian framework with STATA (version 13.0) was done for this study. Results: The database searches yielded 284 titles, with 15 records as duplicates. One study was identified by manually searching. Thirteen articles were included in the systematic review. Twelve studies compared IFN ? (4203 patients) vs another DMT. Four studies evaluated the effectiveness and safety of teriflunomide (906 patients) vs another DMT. Six studies reported drug-induced liver injury as per the Hy's Law. However, only one study had a direct comparison and reported no cases of liver toxicity in either group, so it was not possible to estimate the OR. The indirect comparisons metanalysis shows that there was no statistically-significant difference between teriflunomide and IFN ? (OR 1.09, 95% CI 0.02–2.16). Conclusions: There were no significant difference when comparing IFN ? and teriflunomide in terms of liver failure or elevation of transaminases. © 2018 |
format |
Artículo (Article) |
author |
Salas P.A.O. Parra C.O. Florez C.E.P. Goez L.M. Velez-van-Meerbeke, Alberto Rodriguez J.H. |
author_facet |
Salas P.A.O. Parra C.O. Florez C.E.P. Goez L.M. Velez-van-Meerbeke, Alberto Rodriguez J.H. |
author_sort |
Salas P.A.O. |
title |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
title_short |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
title_full |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
title_fullStr |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
title_full_unstemmed |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
title_sort |
safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: systematic review and indirect comparison meta-analysis |
publisher |
Elsevier B.V. |
publishDate |
2018 |
url |
https://repository.urosario.edu.co/handle/10336/22632 https://doi.org/10.1016/j.msard.2018.09.014 |
_version_ |
1740172572663742464 |
score |
12,131701 |